Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Secukinumab form · 1 trial · 1 indication
Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe |
| Secukinumab 2 mL form | EXPERIMENTAL | Secukinumab 300 mg, provided in a 2 mL pre-filled syringe |
| Secukinumab 1 mL form | ACTIVE_COMPARATOR | Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | 2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48 |
| Secukinumab 2 mL form | DRUG | Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48 |
| Secukinumab 1 mL form | DRUG | Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48 |
Inclusion Criteria: Subjects eligible for inclusion in this study must fulfill all of the following criteria: 1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
Secukinumab form is used to treat psoriasis, a chronic inflammatory skin condition. It is a monoclonal antibody developed by Novartis AG under the ticker NVS. The 2 mL form refers to a pre-filled syringe presentation studied in a Phase 3 clinical trial.
Secukinumab form targets IL17A, a pro-inflammatory cytokine. By binding to IL17A, it acts as an inhibitor of the IL17A signaling pathway, which is involved in the inflammatory process underlying psoriasis. This targeted mechanism is the basis for its development in dermatology.
Secukinumab form is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company responsible for the clinical development of this 2 mL pre-filled syringe formulation of secukinumab.
Secukinumab form is in Phase 3 clinical development. The Phase 3 trial for this 2 mL pre-filled syringe formulation has been completed. It is an investigational product and has not been approved by the FDA for any indication.
Secukinumab form has been studied in one Phase 3 clinical trial, NCT02748863, titled Study of Secukinumab With 2 mL Pre-filled Syringes. This completed trial enrolled 214 participants with psoriasis across multiple countries including the United States, Belgium, Canada, Germany, and others.